We are pleased to announce that a biomedical trial of ARNA Breast Cancer test was started.

ARNA BC clinical trial

The trial is named “An analysis of the effectiveness of the ARNA-BC method for breast cancer diagnostics”. It is conducted by the Personalized Oncology Center of Sechenov First Moscow State Medical University, one of the leading scientific and educational centers of the Russian Federation.

The purpose of this trial is to validate the sensitivity and specificity of ARNA Breast Cancer (ARNA BC) diagnostic test-system. The validation of ARNA BC is blindly performed on blood samples of patients who were already tested by the primary screening diagnostics of breast cancer. So, the ARNA BC test results could be compared to those obtained with traditional screening without knowing the results primary results in advance. The sensitivity and specificity will be validated and estimated using two groups of patients by analysing their liquid biopsy for presence or absence of breast cancer of all types: Luminal A, Luminal B, Her2 / neu, Triple-negative.

The trial will include 100 women aged 18 to 90 years. Half of them should be with the histological confirmation of the diagnosis of breast cancer, half should be made up of healthy volunteers. Some of these days, the first patients will be recruited, and after a while we will get the first results of ARNA BC in medical proof of concept trial. And we are filled with optimism that they will unconditionally confirm the unbeatable data of laboratory trials.

The most valuable properties of any clinical trial are

independent

blind, which means that performer have no any information about the subject of trial, but only track gained results at first. Then the results are unblinded and final protocol is filled out.

We’re accurately following the requirements above not only in order to conform the world standards, but also because we’re using the data gained during the clinical trial to validate ARNA BC with blockchain technology.

When the final data of ongoing clinical trial will be officially unblinded, the accuracy of ARNA BC will be presented in a protocol signed by the officials of Medical Center. Next, ARNA Genomics will publish the protocol and store the results in blockchain in order to make them immutable and validatable any time in future.

Beside the diagnostic test, ARNA Genomics is developing a blockchain-based software named ARNA Panacea. Panacea is an ecosystem using Proof-of-Research protocol based on blockchain and smart-contracts.

How it works:

blockchain is used for time-stamping critical events and data, in order to make clinical trial validatable and reproducible

smart-contracts are used to automise collaboration of many different roles of clinical trials. For example, fulfilling protocols, voting, signing documents.

The Proof-of-Research protocol will allow integration of different blockchains used in the process of a healthcare R&D (Research and Development) process. For example, starting from storing short scientific papers, timestamping preclinical trial, then clinical trial(using ARNA Panacea), and supply chains for pharma-products used during and after clinical trial.

ARNA Panacea will allow to make the whole process of R&D validatable and reproducible. It will decrease friction between participants to the whole process of trial, and increase trust of patients to the final pharma-product developed.

Ultimately, ARNA Panacea blockchain-based ecosystem and Proof-of-Research protocol will allow to make R&D process faster and cheaper.

To support ARNA Genomics, please join our Token Distribution

All participants will be invited to visit our laboratory in Moscow and take the ARNA BC test!

For any questions, write to our support staff in Telegram!